[1] FERRI C P,PRINCE M,BRAYNE C,et al. Global prevalence of dementia:a Delphi consensus study[J]. Lancet,2005,366(9 503):2 112-2 117.
[2]REITZ C,MAYEUX R. Alzheimer disease:epidemiology,diagnostic criteria,risk factors and biomarkers[J]. Biochem pharmacol,2014,88(4):640-651.
[3]MUSSELE S V,BASTARD N L,VERMEIREN Y,et al. Behavioral symptoms in mild cognitive impairment as compared with Alzheimer’s disease and healthy older adults[J]. Int J Geriatr Psych,2013,28(3):265-275.
[4]SPERLING R A,DICKERSON B C,PIHLAJAMAKI M,et al. Functional alterations in memory networks in early Alzheimer’s disease[J]. Neuromol Med,2010,12(1):27-43.
[5]LAZZARO V D,OLIVIERO A,PILATO F,et al. Neurophysiological predictors of long term response to AChE inhibitors in AD patients[J]. J Neurol Neurosur Psychiatry,2005,76(8):1 064-1 069.
[6]MOLINUEVO J L,BERTHIER M L,RAMI L. Donepezil provides greater benefits in mild compared to moderate Alzheimer’s disease:implications for early diagnosis and treatment[J]. Arch gerontol geriat,2011,52(1):18-22.
[7]TSUNO N. Donepezil in the treatment of patients with Alzheimer’s disease[J]. Expert Rev Neurother,2009,9(5):591-598.
[8]SAMADI A,ESTRADA M,PEREZ C,et al. Pyridonepezils,new dual AChE inhibitors as potential drugs for the treatment of Alzheimer’s disease:synthesis,biological assessment,and molecular modeling[J]. Eur J Med Chem,2012,57:296-301.
[9]KRYGER G,SILMAN I,SUSSMAN J L. Structure of acetylcholinesterase complexed with E2020(Aricept):implications for the design of new anti-Alzheimer drugs[J]. Structure with folding and design,1999,7(3):297-307.
[10]NICOLET Y,LOCKRIDGE O,MASSON P,et al. Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products[J]. J Biol Chem,2003,278(42):41 141-41 147.
[11]MORRIS G M,GOODSELL D S,HALLIDAY R S,et al. Automated docking using a lamarckian genetic algorithm and an empirical binding free energy function[J]. J Comput Chem,1998,19(14):1 639-1 662.
[12]CASE D A,CHEATHAM T A,SIMMERLING C L,et al. AMBER10[M]. San Francisco:University of California,2008.
[13]ANDERSEN H C. Molecular dynamics simulations at constant pressure and/or temperature[J]. J Chem Phys,1980,72(4):2 384-2 393.
[14]KOTHANDAN G,CHO S J. Prediction of binding free energy calculation using Molecular Mechanics/Poisson-Boltzmann Surface Area(MM-PBSA)method in drug discovery:a short review[J]. J Chosun Natural Sci,2012,5(4):216-219.
[15]SAIZ U L,CABRERA M A,FROEYEN M. Exploring the conformational changes of the ATP binding site of gyrase B from Escherichia coli complexed with different established inhibitors by using molecular dynamics simulation:protein-ligand interactions in the light of the alanine scanning and free energy decomposition methods[J]. J Mol Graph Model,2011,29(5):726-739.
[16]PAIS F S,RUY PDE C,OLIVEIRA G,et al. Assessing the efficiency of multiple sequence alignment programs[J]. Algorithm Mol Biol,2014,9(4):1-8.